A phase 2 multi-center, randomized, open-label study of two dose levels of IMOxine (IMO-2055 for injection) in patients with metastatic or locally recurrent clear cell renal carcinoma

Trial Profile

A phase 2 multi-center, randomized, open-label study of two dose levels of IMOxine (IMO-2055 for injection) in patients with metastatic or locally recurrent clear cell renal carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2009

At a glance

  • Drugs IMO 2055 (Primary)
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Sep 2009 Final data was presented during the Eighth International Kidney Cancer Symposium 2009, according to Idera Pharmaceuticals.
    • 08 Jan 2009 Status changed from active, no longer recruiting to completed, as reported on ClinicalTrials.gov.
    • 15 Oct 2008 Primary endpoint was not met according to Idera Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top